Thalidomide may impede cell migration in primates by down-regulating integrin β-chains: Potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis

Medical Hypotheses

Volumn 49, Issue 2, 1997, Pages 123-131

  McCarty, M F ^a  

^a Nutrition 21 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN; THALIDOMIDE;

ANGIOGENESIS; CELL MIGRATION; DRUG ACTIVITY; DRUG EFFECT; GENE EXPRESSION REGULATION; HUMAN; HYPOTHESIS; INFLAMMATION; LEUKOCYTE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; REVIEW; TERATOGENESIS;

ORYCTOLAGUS CUNICULUS; PRIMATES;

EID: 0030851993     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(97)90217-6     Document Type: Article

References (108)

1. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965; 6: 303-306.
2. Barnhill R L, McDougall A C. Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J Am Acad Dermatol 1982; 7: 317-323.
3. Hastings R C. Kellersberger Memorial lecture 1979: immunosuppressive/anti-inflammatory thalidomide analogues. Ethiop Med J 1980; 18: 65-71.
4. Hendler S S, McCarty M F. Thalidomide for autoimmune disease. Med Hypotheses 1983; 10: 437-441.
5. Grosshans E, Illy G. Thalidomide therapy for inflammatory dermatoses. Int J Dermatol 1984; 23: 598-602.
6. Samsoen M, Grosshans E, Basset A. La thalidomide dans le traitement du lupus érythémateux chronique. Ann Dermatol Venereol 1980; 107: 515-523.
7. Knop J, Bonsmann G, Happel R et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosis. Br J Dermatol 1983; 108: 461-466.
8. Eisenbud L, Horowitz I, Kay B. Recurrent aphthous stomatitis of the Behcet's type: successful treatment with thalidomide. Oral Surg Oral Med Oral Pathol 1987; 64: 289-292.
9. McCarthy D M, Kanfer E J, Barrett A J. Thalidomide for therapy of graft-versus-host disease following allogeneic bone marrow transplantation. Biomed Pharmacother 1989; 43: 693-697.
10. Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O. Treatment of refractory rheumatoid arthritis - the thalidomide experience. J Rheumatol 1989; 16: 158-163.
11. Tamura F, Vogelsang G B, Reitz R A et al. Combination thalidomide and cyclosporine for cardiac allograft rejection: Comparison with combination methylprednisolone and cyclosporine. Transplantation 1990; 49: 20-25.
12. Heney D, Norfolk D R, Wheeldon J et al. Thalidomide treatment for chronic graft-versus-host disease. Br J Haematol 1991; 78: 23-27.
13. Ryan J, Colman J, Pedersen J, Benson E. Thalidomide to treat esophageal ulcer in AIDS. N Engl J Med 1992; 327: 208-209.
14. Vogelsang G B, Farmer E R, Hess A D et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992; 326: 1055-1058.
15. Bessis D, Guillot B, Montpoint S et al. Thalidomide for systemic lupus erythematosus. Lancet 1992; 339; 549-550.
16. Ghigliotti G, Repetto T, Farris A et al. Thalidomide: treatment of choice for aphthous ulcers in patients seropositive for human immunodeficiency virus. J Am Acad Dermatol 1993; 28: 271-272.
17. D'Amato R J, Loughnan M S, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 1994; 91: 4082-4085.
18. Neubett R, Nogueira A C, Neubert D. Thalidomide and the immune system. 2: Changes in receptors on blood cells of a healthy volunteer. Life Sci 1992; 51: 2107-2116.
19. Neubert R, Nogueira A C, Neubert D. Thalidomide derivatives and the immune system. I: Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood. Arch Toxicol 1993; 67: 1-17.
20. Nogueira A C, Neubert R, Helge H, Neubert D. Thalidomide and the immune system. 3: Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sci 1994; 55: 77-92.
21. Neubert R, Helge H, Neubert D. Thalidomide and the immune system. 4: Down-regulation of the CD26 receptor, probably involved in the binding of HIV components to T cells in primates. Life Sci 1995; 56: 407-420.
22. Hynes R O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
23. Hynes R O, Lander A D. Contact and adhesive specificities in the associations, migrations, and targeting of cells and axons. Cell 1992; 68: 303-322.
24. Springer T A. Adhesion receptors of the immune system. Nature 1990; 346: 425-434.
25. Zimmerman G A, Prescott S M, McIntyre T M. Endothelial cell interactions with granulocytes: tethering and signaling molecules. Immunol Today 1992; 13: 93-99.
26. Neubert R, Hinz N, Thiel R, Neubert D. Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide. Life Sci 1996; 58: 295-316.
27. Bronner-Fraser M. An antibody to a receptor for fibronectin and laminin perturbs cranial neural crest development in vivo. Devel Biol 1986; 117: 528-536.
28. Poole T, Thiery J P. Antibodies and a synthetic peptide that block cell-fibronectin adhesion arrest neural crest cell migration in vivo. In: Slavkin H C, ed. Progress in Developmental Biology. New York: Alan Liss, 1986: 235-238.
29. Darribère T, Yamada K M, Johnson K E, Boucaut J C. The 140-kDa fibronectin receptor complex is required for mesodermal cell adhesion during gastrulation in the amphibian Pleurodeles waltlii. Devel Biol 1988; 126: 182-194.
30. Leavesley D I, Schwartz M A, Rosenfeld M, Cheresh D A. Integrin β1- and β3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J Cell Biol 1993; 121: 163-170.
31. 3 integrin with a small peptide antagonist Gpen-GRGDSPCA. J Vasc Surg 1994; 19: 125-134.
32. Folkman J. What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 1990; 82: 4-6.
33. Blood C H, Zetter B R. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1990; 1032: 89-118.
34. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-10934.
35. Weidner N, Carroll P R, Flax J et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-409.
36. 3 for angiogenesis. Science 1994; 264: 569-571.
37. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-1164.
38. Cheresh D A. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci 1987; 84: 6471-6475.
39. Swerlick R A, Brown E J, Xu Y et al. Expression and modulation of the vitronectin receptor on human dermal microvascular endothelial cells. J Invest Dermatol 1992; 99: 715-722.
40. Ruoslahti E, Reed J C. Anchorage dependence, integrins, and apoptosis. Cell 1994; 77: 471-478.
41. 2. Cancer Res 1991; 51: 903-906.
42. Enenstein J, Waleh N S, Kramer R H. Basic FGF and TGF-β differentially modulate integrin expression of human microvascular endothelial cells. Exp Cell Res 1992; 203: 499-503.
43. 3 subunit with tumor progression. Cancer Res 1990; 50: 6757-6764.
44. 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J Cell Biol 1992; 117: 1101-1107.
45. Sampaio E P, Sarno E N, Galilly R et al. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
46. Sampaio E P, Moreira A L, Sarno E N et al. Prolonged treatment with recombinant interferon γ induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992; 175: 1729-1737.
47. Moreira A L, Sampaio E P, Zmuidzinas A et al. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-1680.
48. Doherty G M, Jensen J C, Alexander H R et al. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 1991; 110: 192-198.
49. Dezube B J, Sherman M L, Fridovich-Keil JL et al. Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study. Cancer Immunol Immunother 1993; 36: 57-60.
50. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316: 379-385.
51. Endres S, Ghorbani R, Kelley V E et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989; 320: 265-271.
52. Makonkawkeyoon S, Limson-Pobre RNR, Moreira AL et al. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci 1993; 90: 5974-5978.
53. McBride W, Lange R A, Hillis L D. Restenosis after successful angioplasty: pathophysiology and prevention. N Engl J Med 1988; 318: 1734-1737.
54. Callow A D. Current status of vascular grafts. Surg Clin North Am 1982; 62: 501-513.
55. Janat M F, Argraves W S, Liau G. Regulation of vascular smooth muscle cell integrin expression by transforming growth factor β1 and by platelet-derived growth factor-BB. J Cell Physiol 1992; 151: 588-595.
56. Basson C T, Kocher O, Basson M D et al. Differential modulation of vascular cell integrin and extracellular matrix expression in vitro by TGF-β1 correlates with reciprocal effects on cell migration. J Cell Physiol 1992; 153: 118-128.
57. Davies J, Warwick J, Totty N et al. The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor. J Cell Biol 1989; 109: 1817-1826.
58. 3 integrin stimulates immediate cell signals in osteoclasts. J Biol Chem 1991; 266: 20369-20374.
59. Ziadi M, Pazianas M, Shankar V S et al. Osteoclast function and its control. Exp Physiol 1993; 78: 721-739.
60. Flores M E, Norgård M, Heinegård D et al. RGD-directed attachment of isolated rat osteoclasts to osteopontin, bone sialoprotein, and fibronectin. Exp Cell Research 1992; 201: 526-530.
61. Sato M, Sardana M K, Grasser W A et al. Echistatin is a potent inhibitor of bone resorption in culture. J Cell Biol 1990; 111: 1713-1723.
62. Delmas P D. Markers of bone formation and resorption. In: Favus M J, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. New York: Raven Press, 1993: 108-112.
63. Ormerod L D, Garsd A, Abelson M B, Kenyon K R. Effects of altering the eicosanoid precursor pool on neovascularization and inflammation in the alkali-burned rabbit cornea. Am J Pathol 1990; 137: 1243-1252.
64. Verbey N L J, van Haeringen N J, de Jong P T V M. Modulation of immunogenic keratitis in rabbits by topical administration of poly-unsaturated fatty acids. Curr Eye Res 1988; 7: 549-556.
65. Kanayasu T, Monta I, Nakao-Hayashi J et al. Eicosapentaenoic acid inhibits tube formation of vascular endothelial cells in vitro. Lipids 1991; 26: 271-276.
66. Reich R, Royce L, Martin G R. Eicosapentaenoic acid reduces the invasive and metastatic activities of malignant tumor cells. Biochem Biophys Res Commun 1989; 160: 559-564.
67. Connolly J M, Rose D P. Effects of fatty acids on invasion through reconstituted basement membrane ('Matrigal') by a human breast cancer cell line. Cancer Lett 1993; 75: 137-142.
68. McCarty M F. Fish oil may impede tumour angiogenesis and invasiveness by down-regulating protein kinase C and modulating eicosanoid production. Med Hypotheses 1996; 46: 107-115.
69. Karmali R A. Dietary ω-3 and ω-6 fatty acids in cancer. In: Galli C, Simopoulos A P, eds. Dietary ω-3 and ω-6 Fatty Acids: Biological Effects and Nutritional Essentiality. New York: Plenum Press, 1989: 351-359.
70. Collie-Duguid E S R, Wahle K W J. Inhibitory effect of fish oil n-3 poly-unsaturated fatty acids on the expression of endothelial cell adhesion molecules. Biochem Biophys Res Commun 1996; 220: 969-974.
71. Nguyen M, Strubel N A, Bischoff J. A role for sialyl Lewis-X/A glyco-conjugates in capillary morphogenesis. Nature 1993; 365: 267-269.
72. Tisdale M J. Inhibition of lipolysis and muscle protein degradation by EPA in cancer cachexia. Nutrition 1996; 12: S31-S33.
73. Wigmore S J, Ross J A, Falconer J S et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 1996; 12: S27-S30.
74. Lee T H, Hoover R L, Williams J D et al. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med 1985; 313: 1217-1221.
75. Sperling R I, Robin J-L, Kylander K A et al. The effects of n-3 polyunsaturated fatty acids on the generation of platelet-activating factor-acether by human monocytes. J Immunol 1987; 139: 4186-4191.
76. Gapinski J P, VanRuiswyk J V, Heudebert G R, Schechtman G S. Preventing restenosis with fish oils following coronary angioplasty. Arch Intern Med 1993; 153: 1595-1601.
77. Powell J S, Clozel J-P, Müller R K M et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245:-186-188.
78. Sakaguchi K, Morita I, Murota S. Eicospentaenoic acid inhibits bone loss due to ovariectomy in rats. Prost Leuk Essent Fatty Acids 1994; 50: 81-84.
79. Buck A C, Davies R L, Harrison T. The protective role of eicosapentaenoic acid [EPA] in the pathogenesis of nephrolithiasis. J Urol 1991; 146: 188-194.
80. Rothwell P J N, Green R, Blacklock N J, Kavanagh J P. Does fish oil benefit stone formers? J Urol 1993; 150: 1391-1394.
81. Moscatelli D, Rifkin D B. Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. Biochim Biophys Acta 1988; 948: 67-85.
82. Mignatti P, Robbins E, Rifkin D B. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 1986; 47: 487-498.
83. Mignatti P, Tsuboi R, Robbins E, Rifkin D B. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol 1989; 108: 671-682.
84. Estreicher A, Wohlwend A, Belin D et al. Characterization of the cellular binding site for the urokinase-type plasminogen activator. J Biol Chem 1989; 264: 1180-1189.
85. Ossowski L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol 1988; 107: 2437-2445.
86. Estreicher A, Mulhauser J, Carpentier J et al. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme complexes. J Cell Biol 1990; 111: 783-792.
87. Hollas W, Blasi F, Boyd D. Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res 1991; 51: 3690-3695.
88. Ossowski L, Clunie G, Masucci M-T, Blasi F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 1991; 115: 1107-1112.
89. Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983; 35: 611-619.
90. Ossowski L. Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. Cell 1988; 52: 321-328.
91. Hearing V J, Law L W, Corti A et al. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 1988; 48: 1270-1278.
92. Kellen J A, Mirakian A, Kolin A. Antimetastatic effect of amiloride in an animal tumour model. Anticancer Res 1988; 8: 1373-1376.
93. Avery R L, Connor T B Jr, Farazdaghi M. Systemic amiloride inhibits experimentally induced neovascularization. Arch Ophthalmol 1990; 108: 1474-1476.
94. Baker M S, Bleakley P, Woodrow G C, Doe W F. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Res 1990; 50: 4676-4684.
95. Kirchheimer J C, Binder B R, Remold H G. Matrix-bound plasminogen activator inhibitor type 1 inhibits the invasion of human monocytes into interstitial tissue. J Immunol 1990; 145: 1518-1522.
96. Ossowski L, Russo-Payne H, Wilson E L. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res 1991; 51: 274-281.
97. Brünner N, Høyer-Hansen G, Rømer J et al. Inhibition of intraperitoneal and metastatic spread of a xenotransplanted human breast carcinoma using a monoclonal antibody directed against the human urokinase-type plasminogen activator. Proc Am Assoc Cancer Res 1992; 33: 61.
98. Billström A, Hartley-Asp B, Lecander I et al. The urokinase inhibitor p-aminobenzamidine inhibits growth of a human prostate tumor in Scid mice. Int J Cancer 1995; 61: 542-547.
99. Evans D M, Lin P L. Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor. Am Surgeon 1995; 61: 692-697.
100. Wilhelm O, Schmitt M, Höhl S et al. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 1995; 13: 296-302.
101. Vassalli J-D, Belin D. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 1987; 214: 187-191.
102. Towle M J, Lee A, Maduakor E C et al. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res 1993; 53: 2553-2559.
103. Birch K A, Heath W F, Hermeling R N et al. LY290181, an inhibitor of diabetes-induced vascular dysfunction, blocks protein kinase C-stimulated transcriptional activation through inhibition of transcription factor binding to a phorbol response element. Diabetes 1996; 45: 642-650.
104. Nerlov C, Rorth P, Blasi F, Johnsen M. Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell-type specific activity. Oncogene 1991; 6: 1583-1592.
105. Gross J L, Moscatelli D, Rifkin D B. Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro. Proc Natl Acad Sci 1983; 80: 2623-2627.
106. Moscatelli D. Urokinase-type and tissue-type plasminogen activators have different distributions in cultured bovine capillary endothelial cells. J Cell Biochem 1986; 30: 19-29.
107. Pepper M S, Vassalli J-D, Montesano R, Orel L. Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J Cell Biol 1987; 105: 2535-2541.
108. Wulff C H, Høyer H, Asboe-Hansen G, Brodthagen H. Development of polyneuropathy during thalidomide therapy. Br J Dermatol 1985; 112: 475-480.